Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event

Reuters

07-21

Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event

Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&D Day event, where the company will review its advanced central nervous system $(CNS)$ pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553947962"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553947962\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553947962?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-21 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553947962","market":"us","top_or_hot":-1,"title":"Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&amp;D Day Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&amp;D Day event, where the company will review its advanced central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-21 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&amp;D Day Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&amp;D Day event, where the company will review its advanced central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL4X4v8g:1","article_id":"2553947962","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553947962","pubTimestamp":1753097426,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&D Day event, where the company will review its advanced central nervous system  pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4505":"高瓴资本持仓","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","AXSM":"Axsome Therapeutics, Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4007":"制药","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据"},"translate_title":"Axsome Therapeutics在研发日活动中公布了AXS-05治疗阿尔茨海默氏焦虑症的有希望的3期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9,"NDAQ":0.9},"content_text":"Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event\n    \n\n        Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&D Day event, where the company will review its advanced central nervous system $(CNS)$ pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}